1、 ARSOV T, LARTER C Z, NOLAN C J, et al. Adaptive failure to high-fat diet characterizes steatohepatitis in Alms1 mutant mice[J].Biochem Biophys Res Commun,2006,342(4):1152-1159. ARSOV T, LARTER C Z, NOLAN C J, et al. Adaptive failure to high-fat diet characterizes steatohepatitis in Alms1 mutant mice[J].Biochem Biophys Res Commun,2006,342(4):1152-1159.
2、 NAKAGAWA H, UMEMURA A, TANIGUCHI K, et al. ER stress cooperates with hypernutrition to trigger TNF-dependent spontaneous HCC development[J].Cancer Cell,2014,26(3):331-343. NAKAGAWA H, UMEMURA A, TANIGUCHI K, et al. ER stress cooperates with hypernutrition to trigger TNF-dependent spontaneous HCC development[J].Cancer Cell,2014,26(3):331-343.
3、 NAKAYAMA H, OTABE S, UENO T, et al. Transgenic mice expressing nuclear sterol regulatory element-binding protein 1c in adipose tissue exhibit liver histology similar to nonalcoholic steatohepatitis[J].Metabolism,2007,56(4):470-475. NAKAYAMA H, OTABE S, UENO T, et al. Transgenic mice expressing nuclear sterol regulatory element-binding protein 1c in adipose tissue exhibit liver histology similar to nonalcoholic steatohepatitis[J].Metabolism,2007,56(4):470-475.
4、 EBERLé D, HEGARTY B, BOSSARD P, et al. SREBP transcription factors: master regulators of lipid homeostasis[J].Biochimie,2004,86(11):839-848. EBERLé D, HEGARTY B, BOSSARD P, et al. SREBP transcription factors: master regulators of lipid homeostasis[J].Biochimie,2004,86(11):839-848.
5、 JIANG S, MINTER L C, STRATTON S A, et al. TRIM24 suppresses development of spontaneous hepatic lipid accumulation and hepatocellular carcinoma in mice[J].J Hepatol,2015,62(2):371-379. JIANG S, MINTER L C, STRATTON S A, et al. TRIM24 suppresses development of spontaneous hepatic lipid accumulation and hepatocellular carcinoma in mice[J].J Hepatol,2015,62(2):371-379.
6、 GANDHI C R, CHAILLET J R, NALESNIK M A, et al. Liver-specific deletion of augmenter of liver regeneration accelerates development of steatohepatitis and hepatocellular carcinoma in mice[J].Gastroenterology,2015,148(2):379-391.e4. GANDHI C R, CHAILLET J R, NALESNIK M A, et al. Liver-specific deletion of augmenter of liver regeneration accelerates development of steatohepatitis and hepatocellular carcinoma in mice[J].Gastroenterology,2015,148(2):379-391.e4.
7、 HORIE Y, SUZUKI A, KATAOKA E, et al. Hepatocyte-specific PTEN deficiency results in steatohepatitis and hepatocellular carcinomas[J].J Clin Invest,2004, 113(12):1774-1783. HORIE Y, SUZUKI A, KATAOKA E, et al. Hepatocyte-specific PTEN deficiency results in steatohepatitis and hepatocellular carcinomas[J].J Clin Invest,2004, 113(12):1774-1783.
8、 CHEN C Y, CHEN J, HE L, et al. PTEN: Tumor Suppressor and Metabolic Regulator[J].Front Endocrinol (Lausanne),2018(9):338. CHEN C Y, CHEN J, HE L, et al. PTEN: Tumor Suppressor and Metabolic Regulator[J].Front Endocrinol (Lausanne),2018(9):338.
9、 HAINER V, ALDHOON HAINEROVá I, KUNE?OVá M, et al. Melanocortin pathways: suppressed and stimulated melanocortin-4 receptor (MC4R)[J].Physiol Res,2020,69(Suppl 2):S245-S254. HAINER V, ALDHOON HAINEROVá I, KUNE?OVá M, et al. Melanocortin pathways: suppressed and stimulated melanocortin-4 receptor (MC4R)[J].Physiol Res,2020,69(Suppl 2):S245-S254.
10、 ITOH M, SUGANAMI T, NAKAGAWA N, et al.Melanocortin 4 receptor-deficient mice as a novel mouse model of nonalcoholic steatohepatitis[J].Am J Pathol,2011, 179(5):2454-2463. ITOH M, SUGANAMI T, NAKAGAWA N, et al.Melanocortin 4 receptor-deficient mice as a novel mouse model of nonalcoholic steatohepatitis[J].Am J Pathol,2011, 179(5):2454-2463.
11、 VéNIANT M M, WITHYCOMBE S, YOUNG S G.Lipoprotein size and atherosclerosis susceptibility in Apoe(-/-) and Ldlr(-/-) mice[J].Arterioscler Thromb Vasc Biol, 2001,21(10):1567-1570. VéNIANT M M, WITHYCOMBE S, YOUNG S G.Lipoprotein size and atherosclerosis susceptibility in Apoe(-/-) and Ldlr(-/-) mice[J].Arterioscler Thromb Vasc Biol, 2001,21(10):1567-1570.
12、 HUEBBE P, RIMBACH G.Evolution of human apolipoprotein E (APOE) isoforms: Gene structure, protein function and interaction with dietary factors[J].Ageing Res Rev,2017(37):146-161. HUEBBE P, RIMBACH G.Evolution of human apolipoprotein E (APOE) isoforms: Gene structure, protein function and interaction with dietary factors[J].Ageing Res Rev,2017(37):146-161.
13、 SUBRAMANIAN S, GOODSPEED L, WANG S, et al. Dietary cholesterol exacerbates hepatic steatosis and inflammation in obese LDL receptor-deficient mice[J].J Lipid Res,2011,52(9):1626-1635. SUBRAMANIAN S, GOODSPEED L, WANG S, et al. Dietary cholesterol exacerbates hepatic steatosis and inflammation in obese LDL receptor-deficient mice[J].J Lipid Res,2011,52(9):1626-1635.
14、 GO G W, MANI A.Low-density lipoprotein receptor (LDLR) family orchestrates cholesterol homeostasis[J].Yale J Biol Med,2012,85(1):19-28. GO G W, MANI A.Low-density lipoprotein receptor (LDLR) family orchestrates cholesterol homeostasis[J].Yale J Biol Med,2012,85(1):19-28.
15、 ZHANG Y, CHUA S Jr.Leptin function and regulation[J].Compr Physiol,2017,8(1):351-369. ZHANG Y, CHUA S Jr.Leptin function and regulation[J].Compr Physiol,2017,8(1):351-369.
16、 MINAMI Y, YUAN Y, UEDA H R.High-throughput genetically modified animal experiments achieved by next-generation mammalian genetics[J].J Biol Rhythms,2022, 37(2):135-151. MINAMI Y, YUAN Y, UEDA H R.High-throughput genetically modified animal experiments achieved by next-generation mammalian genetics[J].J Biol Rhythms,2022, 37(2):135-151.
17、 LI X, WU Y, ZHAO J, et al. Distinct cardiac energy metabolism and oxidative stress adaptations between obese and non-obese type 2 diabetes mellitus[J].Theranostics, 2020,10(6):2675-2695. LI X, WU Y, ZHAO J, et al. Distinct cardiac energy metabolism and oxidative stress adaptations between obese and non-obese type 2 diabetes mellitus[J].Theranostics, 2020,10(6):2675-2695.
18、 FUJII M, SHIBAZAKI Y, WAKAMATSU K,et al. A murine model for non-alcoholic steatohepatitis showing evidence of association between diabetes and hepatocellular carcinoma[J].Med Mol Morphol,2013,46(3):141-152. FUJII M, SHIBAZAKI Y, WAKAMATSU K,et al. A murine model for non-alcoholic steatohepatitis showing evidence of association between diabetes and hepatocellular carcinoma[J].Med Mol Morphol,2013,46(3):141-152.
19、 WELTMAN M D, FARRELL G C, LIDDLE C.Increased hepatocyte CYP2E1 expression in a rat nutritional model of hepatic steatosis with inflammation[J].Gastroenterology, 1996,111(6):1645-1653. WELTMAN M D, FARRELL G C, LIDDLE C.Increased hepatocyte CYP2E1 expression in a rat nutritional model of hepatic steatosis with inflammation[J].Gastroenterology, 1996,111(6):1645-1653.
20、 RINELLA M E, ELIAS M S, SMOLAK R R, et al. Mechanisms of hepatic steatosis in mice fed a lipogenic methionine choline-deficient diet[J].J Lipid Res,2008, 49(5):1068-1076. RINELLA M E, ELIAS M S, SMOLAK R R, et al. Mechanisms of hepatic steatosis in mice fed a lipogenic methionine choline-deficient diet[J].J Lipid Res,2008, 49(5):1068-1076.
21、 FAN J G, CAO H X.Role of diet and nutritional management in non-alcoholic fatty liver disease[J].J Gastroenterol Hepatol,2013,28(Suppl 4):81-87. FAN J G, CAO H X.Role of diet and nutritional management in non-alcoholic fatty liver disease[J].J Gastroenterol Hepatol,2013,28(Suppl 4):81-87.
22、 SANTHEKADUR P K, KUMAR D P, SANYAL A J.Preclinical models of non-alcoholic fatty liver disease[J].J Hepatol,2018,68(2):230-237. SANTHEKADUR P K, KUMAR D P, SANYAL A J.Preclinical models of non-alcoholic fatty liver disease[J].J Hepatol,2018,68(2):230-237.
23、 COLE B K, FEAVER R E, WAMHOFF B R, et al. Non-alcoholic fatty liver disease (NAFLD) models in drug discovery[J].Expert Opin Drug Discov,2018,13(2):193-205. COLE B K, FEAVER R E, WAMHOFF B R, et al. Non-alcoholic fatty liver disease (NAFLD) models in drug discovery[J].Expert Opin Drug Discov,2018,13(2):193-205.
24、 ASGHARPOUR A, CAZANAVE S C, PACANA T, et al.A diet-induced animal model of non-alcoholic fatty liver disease and hepatocellular cancer[J].J Hepatol,2016, 65(3):579-588. ASGHARPOUR A, CAZANAVE S C, PACANA T, et al.A diet-induced animal model of non-alcoholic fatty liver disease and hepatocellular cancer[J].J Hepatol,2016, 65(3):579-588.
25、 TSUCHIDA T, LEE Y A, FUJIWARA N,et al. A simple diet- and chemical-induced murine NASH model with rapid progression of steatohepatitis, fibrosis and liver cancer[J].J Hepatol,2018,69(2):385-395. TSUCHIDA T, LEE Y A, FUJIWARA N,et al. A simple diet- and chemical-induced murine NASH model with rapid progression of steatohepatitis, fibrosis and liver cancer[J].J Hepatol,2018,69(2):385-395.
26、 TACKE F, WEISKIRCHEN R.Non-alcoholic fatty liver disease (NAFLD)/non-alcoholic steatohepatitis (NASH)-related liver fibrosis: mechanisms, treatment and prevention[J].Ann Transl Med,2021,9(8):729. TACKE F, WEISKIRCHEN R.Non-alcoholic fatty liver disease (NAFLD)/non-alcoholic steatohepatitis (NASH)-related liver fibrosis: mechanisms, treatment and prevention[J].Ann Transl Med,2021,9(8):729.
27、 LOOMBA R, FRIEDMAN S L, SHULMAN G I.Mechanisms and disease consequences of nonalcoholic fatty liver disease[J].Cell,2021,184(10):2537-2564. LOOMBA R, FRIEDMAN S L, SHULMAN G I.Mechanisms and disease consequences of nonalcoholic fatty liver disease[J].Cell,2021,184(10):2537-2564.
28、 TARGHER G, BYRNE C D, TILG H.NAFLD and increased risk of cardiovascular disease: clinical associations, pathophysiological mechanisms and pharmacological implications[J].Gut,2020,69(9):1691-1705. TARGHER G, BYRNE C D, TILG H.NAFLD and increased risk of cardiovascular disease: clinical associations, pathophysiological mechanisms and pharmacological implications[J].Gut,2020,69(9):1691-1705.
29、 ADAMS L A, ANSTEE Q M, TILG H, et al. Non-alcoholic fatty liver disease and its relationship with cardiovascular disease and other extrahepatic diseases[J].Gut, 2017,66(6):1138-1153. ADAMS L A, ANSTEE Q M, TILG H, et al. Non-alcoholic fatty liver disease and its relationship with cardiovascular disease and other extrahepatic diseases[J].Gut, 2017,66(6):1138-1153.
30、 ZHOU J, BAI L, ZHANG X J, et al. Nonalcoholic fatty liver disease and cardiac remodeling risk: Pathophysiological mechanisms and clinical implications[J].Hepatology,2021,74(5):2839-2847. ZHOU J, BAI L, ZHANG X J, et al. Nonalcoholic fatty liver disease and cardiac remodeling risk: Pathophysiological mechanisms and clinical implications[J].Hepatology,2021,74(5):2839-2847.
31、 TAN D J H, NG C H, LIN S Y, et al. Clinical characteristics, surveillance, treatment allocation, and outcomes of non-alcoholic fatty liver disease-related hepatocellular carcinoma: a systematic review and meta-analysis[J].Lancet Oncol,2022, 23(4):521-530. TAN D J H, NG C H, LIN S Y, et al. Clinical characteristics, surveillance, treatment allocation, and outcomes of non-alcoholic fatty liver disease-related hepatocellular carcinoma: a systematic review and meta-analysis[J].Lancet Oncol,2022, 23(4):521-530.
32、 COTTER T G, RINELLA M.Nonalcoholic Fatty Liver Disease 2020: The State of the Disease[J].Gastroenterology,2020,158(7):1851-1864. COTTER T G, RINELLA M.Nonalcoholic Fatty Liver Disease 2020: The State of the Disease[J].Gastroenterology,2020,158(7):1851-1864.
33、 FRIEDMAN S L, NEUSCHWANDER-TETRI B A, RINELLA M,et al. Mechanisms of NAFLD development and therapeutic strategies[J].Nat Med,2018,24(7):908-922. FRIEDMAN S L, NEUSCHWANDER-TETRI B A, RINELLA M,et al. Mechanisms of NAFLD development and therapeutic strategies[J].Nat Med,2018,24(7):908-922.
34、 SHEKA A C, ADEYI O, THOMPSON J,et al.Nonalcoholic steatohepatitis: A review[J].JAMA,2020,323(12):1175-1183. SHEKA A C, ADEYI O, THOMPSON J,et al.Nonalcoholic steatohepatitis: A review[J].JAMA,2020,323(12):1175-1183.
